APOTHEEK VAN HULST
ActiveSummary
APOTHEEK VAN HULST has been active since 1983 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €128,686 and a net result of €122,782. Equity has been stable since 2019 (±0.5% per year). Its solvency ranks better than 32% of 12,777 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
Source: KBO- Status
- Active since 15-11-1983 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 30-06-2025
- Establishment unit
- 2.023.337.351 2180 Antwerpen, since 01-01-1984
- Financial year end
- 30 June
- Peppol
- Reachable since 08-01-2026
Board and ownership
- EFRAXDirector · since 08-11-2023 · permanent representative FRANCK Eric Adriaan Margaretha
- VAN HULST WIMDirector · since 08-11-2023
- Van Hulst Wim75.04%2025 annual accounts of Van Hulst Wim
- EFRAX24.96%30-09-2025 annual accounts of EFRAX
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €285,328
- ▲ 3.8%
- Turnover
- ≈ €1.0m
- estimated
- Profit
- €122,782
- ▲ 27.5%
- Equity
- €128,686
- ▲ 2.2%
- Total assets
- €613,381
- ▲ 13.9%
- Employees on 30-06-2025
- 4
- =
Score breakdownraises riskSector: Retail trade (NACE 47)Equity €128,686 (21.0% of total assets)lowers riskFounded in 1983Liquidity: current ratio 1.33, cash €142,016Show the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 37% of them on solvency, 47% on liquidity, 88% on profitability and 46% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 21 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed 3 directors appointed, 3 directors resigningResignations: EFRAX (director) and VAN HULST WIM (director) · Appointments: EFRAX (director) and VAN HULST WIM (director) · Permanent representatives: FRANCK Eric Adriaan Margaretha and VAN HULST Wim
- · Gazette deed Amendment of the articles · Resignations & appointments
Comparable companies
These companies have the same main activity as APOTHEEK VAN HULST: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €552,000 and €725,000, founded between 1980 and 1988.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK VAN HULST Antwerpen | €613,381 | €285,328 |
| APOTEEK GINDERBUITEN Mol | €692,197 | €304,987 |
| Apotheek Veramme - Casier Wetteren | €614,611 | €296,532 |
| CORUM MARIAKERKE Gent | €666,044 | €251,689 |
| HEMIFAR Hemiksem | €724,505 | €315,391 |
| Apotheek De Gendt Antwerpen | €551,792 | €360,393 |
| NAVEAU-SMEETS Lint | €552,659 | €237,388 |
Key facts about APOTHEEK VAN HULST
- What is the company number of APOTHEEK VAN HULST?
- The company number of APOTHEEK VAN HULST is 0424.867.027. The VAT number is the same number with BE in front: BE 0424.867.027.
- Where is APOTHEEK VAN HULST based?
- The registered office is at Driehoekstraat 91, 2180 Antwerpen.Company details
- What does APOTHEEK VAN HULST do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK VAN HULST?
- The legal form of APOTHEEK VAN HULST is Public limited company (NV).
- When was APOTHEEK VAN HULST founded?
- APOTHEEK VAN HULST was founded on 15-11-1983.
- Is APOTHEEK VAN HULST still active?
- Yes, APOTHEEK VAN HULST is an active enterprise in the KBO register.
- How many employees does APOTHEEK VAN HULST have?
- APOTHEEK VAN HULST had an average of 2.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does APOTHEEK VAN HULST fall under?
- In its 30-06-2025 annual accounts, APOTHEEK VAN HULST states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of APOTHEEK VAN HULST?
- The turnover in financial year 2025 is ≈ €1.0m. This figure is estimated from the gross margin of €285,328 and 47 comparable companies (NACE 477). It probably lies between €810,000 and €1.7m.
- Is APOTHEEK VAN HULST profitable?
- In financial year 2025, APOTHEEK VAN HULST made a profit of €122,782.
- Where can I find the annual accounts of APOTHEEK VAN HULST?
- APOTHEEK VAN HULST filed 41 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of APOTHEEK VAN HULST due?
- APOTHEEK VAN HULST must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.